Komori
Changes in Officers4577Daito Pharmaceutical Co.,Ltd.Pharmaceuticals

Notice of Changes to Directors

Ishida Toru (石田 徹) will remain a director and managing executive officer, and will additionally serve concurrently as head of the Environmental Safety Office alongside his role as head of the Production Division. He will no longer serve as head of the Formulation Manufacturing Department.

Worth reading
22Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Who is moving to which position

Incoming appointee

1 item
Scheduled Appointment Date1 June 2026
Ishida Toru (石田 徹)
Previous positionDirector, Managing Executive Officer, Head of Production Division, Head of Formulation Manufacturing Department and Head of Environmental Safety Office
New positionDirector, Managing Executive Officer, Head of Production Division and Head of Environmental Safety Office
Who is moving to which position
ItemDetails
Scheduled Appointment Date1 June 2026
Name of appointeeIshida Toru (石田 徹)
Appointee's new positionDirector, Managing Executive Officer, Head of Production Division and Head of Environmental Safety Office
Appointee's previous positionDirector, Managing Executive Officer, Head of Production Division, Head of Formulation Manufacturing Department and Head of Environmental Safety Office
Items this document does not state (17)
Resolution dateDate of departureAppointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeName of departing officerFormer position of departing officerNew position of departing officerReason for departureWhether the incumbent will remain in officeReason for changeReasons for appointmentNumber of directors after the changeFiling as an independent officerDetails of organizational changesChange in Corporate Governance StructureSubject to Approval by the General Meeting of Shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

No reason for the changes is provided.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Changes to Directors | Daito Pharmaceutical Co.,Ltd. (4577) timely disclosure | Komori